
拥有 40 年历史的中东和北非制药公司

EBITDA
$6,279,944
Gross
$37,000,000
Global lower-middle market M&A Advisors
Countries in which we've closed transactions
Languages spoken by our Team
Total deals value
Global lower-middle market M&A Advisors
Countries in which we've closed transactions
Languages spoken by our Team
Total deals value
© 2025 MergersCorp M&A International.
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
这家制药公司在约旦安曼成立,已有 40 年左右的历史。 它拥有 70 多项专利,在创新方面保持着区域标杆。作为这一创新的直接结果,通过将成熟的技术平台分拆为拥有独� ...
这家制药公司在约旦安曼成立,已有 40 年左右的历史。 它拥有 70 多项专利,在创新方面保持着区域标杆。
作为这一创新的直接结果,通过将成熟的技术平台分拆为拥有独立管理和资源的子公司,业务在传统仿制药行业之外实现了多元化。
1.核心品牌仿制药业务。
2.通过子公司天然产物。
3.通过子公司进行生物技术诊断。
4. 通过子公司开发新型赋形剂和给药系统。
产品涵盖广泛的治疗类别,包括心血管、胃肠道、中枢神经系统、抗感染、内分泌、肌肉骨骼、呼吸、产科、妇科和泌尿道以及免疫系统。
它提供 200 多种药品,满足消费者和医疗保健专业人员的需求。 这些产品包括片剂、胶囊、栓剂、糖浆和混悬剂,均按照良好生产规范 (GMP) 生产。 该公司具有竞争优势,使其成为领先的制药公司之一,因为其产品具有高“质量”。
它被誉为中东最好的公司之一,专门利用标准化药用植物提取物开发和生产植物和草药产品,提供 50 多种天然和草药创新产品,业务遍及全球 20 多个国家 。
它是一家专门从事生产专有生物技术保健产品的开发商和生产商。
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
This website is operated by MergersUS Inc a US Corporation with registered office at
报错: 未找到这个表单
报错: 未找到这个表单
报错: 未找到这个表单
报错: 未找到这个表单
报错: 未找到这个表单